Biotech company avoids DOJ charges after self-reporting payment of bribes

Lifecore Biomedical, Inc.’s efforts in self-reporting FCPA violations lead to declination decision from DOJ.

Lifecore Biomedical, Inc., formerly known as Landec Corporation, has received a declination with disgorgement from the US Department of Justice (DOJ) for Foreign Corrupt Practices Act (FCPA) violations in Mexico. The company is a biotech firm with its principal offices in California but is incorporated in Delaware.

The DOJ’s declination

Free Trial

Register for free to keep reading.

To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.

  • Unlimited access to industry insights
  • Stay on top of key rules and regulatory changes with our Rules Navigator
  • Ad-free experience with no distractions
  • Regular podcasts from trusted external experts
  • Fresh compliance and regulatory content every day
Register for free Already a member? Sign in